Kelly Martin has served as our President and Chief Executive Officer since April 2020.
For over a decade, Kelly was CEO of Elan Corporation plc, an Ireland-based pharmaceutical company focused on neurodegenerative diseases. The company was sold to the Perrigo Company in 2013. Since Elan, Kelly has held positions within the life sciences industry including having served as interim CEO of Novan, Inc., a clinical-stage nitric oxide biotechnology company. He is currently Executive Chairman of Wren Therapeutics Limited, a UK-based company focused on the chemical kinetics of the protein misfolding process.
Kelly’s professional career started in finance having spent 22 years at Merrill Lynch & Co. Inc., where over the course of his career he worked in Tokyo, London, and New York. During that time, he had the opportunity to lead several global operating divisions for the company.